

Pilot Genome wide Linkage Analysis in Asian Indian Families with Coronary Artery Disease

Jayashree Shanker*¹, Arindam Maitra¹, Prathima Arvind¹, Jiny Nair¹, Debabrata Dash¹, Shibu John², Pratibha Siwach¹, Veena S Rao³, H Sridhara², Vijay V Kakkar^{4,5}

- 1 Mary & Garry Weston Functional Genomics Unit, Thrombosis Research Institute India, Bangalore.
- 2 Elizabeth & Emmanuel Kaye Bioinformatics and Statistics Unit, Thrombosis Research Institute India, Bangalore.
- 3 Tata Proteomics & Coagulation Unit, Thrombosis Research Institute India, Bangalore.

- 4 Scientific Chairman and Founder Director, Thrombosis Research Institute India, Bangalore.
- 5 President, Thrombosis Research Institute, London.

* Corresponding Author:
✉ jayashrees Shanker@triindia.org.in

Head, Mary & Garry Weston Functional Genomics Unit Thrombosis Research Institute India.
Narayana Hrudayalaya Hospital, 258/A Bommasandra Industrial Area, Anekal Taluk Bangalore 560099, India.
Telephone: +91-80-27835303,
Fax: +91-80-27835302.

Abstract

Background and Objectives: Asian Indians show an inherent predisposition to premature Coronary Artery Disease (CAD) with a strong family history and therefore serve as a suitable population for identifying novel genes linked to CAD. We performed pilot linkage analysis on a subset of Asian Indian families selected from the *Indian Atherosclerosis Research Study* (IARS) to identify putative loci linked to CAD.

Methods & Findings: We performed linkage study on six multiplex families consisting of 31 affected sibling pairs (ASPs). Families were ascertained through the proband who had angiographically confirmed CAD, with age at onset < 60 years for males and <65 years for females. *Linkage mapping set v 2.5-MD10*, comprising of 400 fluorescent labeled microsatellite markers were genotyped in 31 ASPs. Quantitative trait loci (QTL) analysis was carried out for sixteen atherothrombotic biomarkers and non parametric linkage analysis was performed by affected sib-pair method. There was suggestive evidence of linkage at 4q21.21, 6q22.33, 6q23, 6q24.2 and 8q24.1 to CAD (Logarithm of Odds – LOD score ≥ 1 ; $p < 0.05$). Bioinformatics analysis of significant linkage peaks identified key genes associated with inflammation and immune response. QTL analysis revealed suggestive evidence of linkage to Xp22.3 locus for total cholesterol (LOD =1.7) and at various loci on chromosomes 1,2,4,11 and X for Fibrinogen, Interleukin 2, Apolipoprotein A1, High density lipoprotein cholesterol and Apolipoprotein B (LOD >1; $p < 0.05$), respectively.

Conclusion: Novel loci on chromosome 4,6 and 8 has shown suggestive evidence of linkage to CAD in this initial study; their role in the etio-pathogenesis of CAD remains to be established

Key words: affected sibling pair, Asian Indians, coronary artery disease, linkage, microsatellite markers.



This article is available from:
www.transbiomedicine.com

Introduction

Coronary Artery Disease (CAD) is a common cause of death and disability in the world. Presence of strong family history and premature disease onset in Asian Indians indicate a significant role for genetic factors in the etiopathogenesis of CAD (1). In this regard, the Indian Atherosclerosis Research Study (IARS), a genetic epidemiological study, comprising of CAD patients and their relatives with strong family history of cardiovascular disease (CVD), offers a suitable platform to investigate the contribution of genetic factors (2).

Non-parametric linkage analysis based on affected sibling pairs (ASPs) serves as a useful method to test for linkage between microsatellite markers and CAD (3). A number of linkage studies have been reported on ASPs that have helped to identify specific CAD loci on chromosome 1, 2, 3, 7, 16, 20, X etc (4-11). The key issues with linkage analysis have been their limited success in identifying putative candidate genes for CAD and the lack of reproducibility of the study findings that has been attributed to factors such as different cohort sizes, variable clinical phenotype, gene-environment interactions etc. Nevertheless, studies undertaking fine mapping of loci with significant linkage have been moderately successful in identifying novel CAD genes such as KALRN, NPY, FAM5C, MEF2A etc (8, 10-12). Furthermore, studies on quantitative trait loci (QTL) have identified several interesting novel loci linked to various candidate atherothrombotic biomarkers namely lipids (13-15), inflammation (16), coagulation (17), obesity markers (18), vascular markers of sub clinical atherosclerosis (19) and so on.


Despite the enormous burden of heart disease in India, there is very limited information on the genetic architecture of Indians (17, 20-33); what little is known suggests that the Indian population is a genetic potpourri of unique social and religious divides that makes it a very interesting topic for study. Availability of large multiplex families in the IARS provides opportunities to unravel the genetic risk factors for CAD. This paper discusses the findings of a pilot linkage study performed on six multiplex families selected from the IARS cohort, comprising of 31 ASPs, with an objective to identify novel loci for CAD as well as QTL loci for candidate biomarkers in a predisposed cohort of Asian Indians.

Methods

Study Cohort

A total of six families comprising of 21 CAD affected siblings and 10 unaffected siblings were selected from the ongoing Indian Atherosclerosis Research Study (IARS) cohort. These subjects were enrolled during May 2004 to May 2005 in Phase I of the study and comprised of CAD patients, their affected and unaffected family members including siblings, spouse, offspring above 18 years of age and parents. There was a total of 31 ASPs - 1 family each with 15 ASPs (family # 87), 6 ASPs (family # 76) and 1 ASP (family # 232) and 3 families with 3 ASPs (family # 13, #131, #232), respectively (Fig. 1).

Figure 1. Pedigree of six families selected for linkage study.



A detailed design of the IARS has been previously described (2). To describe briefly, the IARS is an ongoing epidemiological study, with an objective to investigate the genetic factors associated with CAD, as also their interaction with traditional risk factors among Asian Indians living in India. Family members were recruited through the proband with history of premature CAD from Narayana Hrudayalaya multispecialty hospital and other hospital/clinics in Bangalore city and from the Asian Heart Institute in Mumbai, India. Representative participants were recruited from North, South, East and West of India. Patients showed clinical evidence of stable / unstable angina or myocardial infarction event, diagnosed by coronary angiogram and echocardiogram (ECG) and treated with standard medication or coronary angiography followed by percutaneous transluminal coronary angioplasty (PTCA) or coronary artery bypass graft (CABG). Proband was selected based on predefined inclusion-exclusion criteria which included those having age of disease onset 60 years or less for men and 65 years or less for women. Unaffected subjects were asymptomatic at recruitment and showed normal ECG readings. Participants were not suffering from any other major illness at the time of enrolment and were free of concomitant infection. Participation in the study was by informed, signed, voluntary consent. The IARS protocol has been approved by the institutional ethics committee and designed as per the Indian Council of Medical Research (ICMR) guidelines on bioethics (34).

All study participants provided fasting blood and urine samples. Detailed demographics, anthropometrics, vital parameters, medical history, medication and pedigree information were recorded for each participant through personal interviews. Prevalence of type 2 diabetes, hypertension and CVD was ascertained based on self-report of physician's diagnosis and/or use of prescription medications along with perusal of medical records.

DNA extraction and Genotyping

Genomic DNA was isolated from whole blood using salting out procedure (35) and quantified using Nanodrop ND-1000 (Thermo Scientific, Washington, USA) and real time polymerase chain reaction (RT-PCR, Applied Biosystems, USA). The ABI Prism Linkage Mapping Set v 2.5-MD10 that comprises of 400 fluorescent labeled microsatellite markers, spaced approximately 10cM apart and covers the entire whole genome, was used for linkage analysis. Thermal cycling conditions for PCR were based on manufacturer's instructions. Following amplification, the PCR products were pooled along with Gene Scan™- 500 LIZ™ size standard and analyzed on ABI Prism 3130XL genetic analyzer. Commercially available CEPH DNA sample as well as two in-house samples was used for quality control. Following standardization, PCR amplifica-

tion and analysis was carried out in two batches of 14 and 22 samples. CEPH DNA was used as positive control with each batch of PCR set up, 3130XL run and during analysis.

Genotyping and assignment of Allele calls

Genotyping based on allele calls were performed using *GeneMapper version 4.0* software (ABI, USA) and a macros based algorithm that was developed in-house. All genotypes, including those that passed the internal quality control of GeneMapper were manually read and independently verified by at least two individuals. Genotypes were rejected and samples were re-analyzed in case there was no consensus on the allele calls. The *PedCheck* program (36) was used to detect genotype inconsistencies, not in agreement with the Mendelian inheritance pattern. Such genotypes were re-analyzed and either corrected, or else deleted from the study.

Linkage analysis

Non Parametric linkage analysis was performed based on the affected sibling pair method to test for linkage between microsatellite markers and CAD (3). *MERLIN* program was used for linkage analysis (37). Appropriate input files were created using *Mega2* (38). Both single point and multipoint linkage analysis was performed using the *MERLIN_{all}* and *MERLIN_{pairs}* options in *MERLIN*. Significant linkage was calculated based on LOD score value. LOD stands for logarithm of the odds (to the base 10). Linkage was assigned based on predefined significance criteria (39).

Analysis of Quantitative trait loci (QTL)

QTL analysis was performed for various candidate biomarkers. For the purpose of measuring biomarker levels, venous blood was collected in evacuated tubes after an overnight fast of 12 to 14 hours (Vacurette®, Greiner Bio-One GmbH, Vienna, Austria). Serum cholesterol and triglycerides were estimated by standard enzymatic analysis following manufacturer's guidelines (Randox Laboratories, UK); High Density Lipoprotein-Cholesterol (HDL-c) was estimated after precipitation of non-HDL fractions with a mixture of 2.4mmol/l phosphotungstic acid and 39mmol/l magnesium chloride and Low Density lipoprotein-cholesterol (LDL-c) was calculated using Friedwald formula (40). Immunoturbidimetry was employed to measure Lipoprotein(a) levels using reagents from Randox Laboratories, UK; Apolipoproteins A1 and B100 were measured with reagents from Orion Diagnostica, Finland in a Cobas-Fara II Clinical Chemistry Autoanalyser (Roche, Switzerland). Normal human serum pool (NHP) was prepared in-house and run with each batch of tests. The inter assay coefficients of variation (CV) for commercial controls and NHP range was 4.9-7.0% for total cholesterol, 6.1-7.7% for triglyceride, 7.1-

12.2% for HDL-cholesterol, 3.3-5.2% for Lp(a), 9.9-14.2% and 10.7-13.9% for apolipoprotein A1 and B100 respectively. Plasma Interleukin 6 was measured by ELISA (R&D systems, USA); interassay CV for NHP was 4.3%. Plasma hsCRP levels were measured using the Roche latex Tina quant kit (Roche Diagnostics, Switzerland); interassay CV of NHP was 7.85%. secretory phospholipase A2 levels were determined using a sandwich immunoassay specific for type IIa (Cayman Corporation, USA) with a sensitivity limit of 15pg/ml; interassay CV of NHP was 5.37%.

Height, weight, waist and hip circumference and blood pressure (BP) was measured for each participant. BMI was calculated as a ratio of weight in kg to height in meter². The 'QTL' option in MERLIN program was used for linkage analysis for these quantitative traits.

Results

Cohort

There were 17 males and 4 females in the CAD affected group (N=21) and 6 males and 9 females in the unaffected sibling group (N=15). Frequencies of diabetes and smokers were higher among the affected subjects. Mean age at onset was 50.47 years for males and 59.50 years for females.

Table 1 provides a summary of clinical profile of the study participants.


Linkage analysis to CAD

We utilized the data obtained from the affected sibling group only for performing linkage analysis,. Based on analysis on 31 ASPs from 6 multiplex families, we observed suggestive

Table 1. Clinical profile of study participants.

Description	CAD affected (N=21)		Unaffected siblings (N=15)	
	Male (N=17)	Female (N=4)	Male (N=6)	Female (N=9)
Mean age	61 y	64.75 y	43.83 y	53.22 y
Diabetes	8 (47%)	2 (50%)	1 (16.7%)	2 (22.2%)
Hypertension	2 (11.8%)	4 (100%)	3 (50%)	5 (55.6%)
Ever smoked	14 (82.4%)	-	2 (33.3%)	-
Mean age at CAD onset	50.47 y	59.5 y	-	-

Figure 2. Individual value plot of LOD score plotted against chromosome number for the 400 microsatellite markers.



evidence of linkage for CAD at 4q21.21, 6q22.33, 6q23 and 6q24.2 and 8q24.1 with a LOD score value of ~ 1 at a nominal significance of $p < 0.05$. **Table 2** summarizes the list of all microsatellite markers that show a LOD score >0.40 while **Fig. 2** depicts loci showing suggestive evidence of linkage to CAD. Age and gender were used as covariates.

Analysis of Quantitative Trait Loci (QTL)

QTL analysis showed suggestive evidence of linkage at chromosome Xp22.3 for TC (LOD=1.7), and various loci on chromosomes 1, 2, 4, 11 and X for fibrinogen, IL2, ApoA1, HDL-c and ApoB (LOD score above 1), respectively (**Fig. 3**). Interestingly, D13S159 marker showed significant suggestive linkage to 13q32.2 region (LOD=0.9), a validated locus for the F7 gene. The complete list of suggestive quantitative trait loci with LOD score >0.88 for the various biomarkers are shown in **Table 3**.

Bioinformatics analysis

We performed bioinformatics analysis on putative candidate genes underlying loci that showed suggestive evidence of linkage to CAD ($P < 0.05$). For this, we used the NCBI database to identify all those genes lying at approximately 1 LOD unit (1Mb) upstream and downstream from those microsatellite markers showing suggestive linkage to CAD (**Figure 2**). We identified several interesting genes or gene products. The APO A1 gene located on 4q21 locus that encodes for Apolipoprotein A1 and PLA2G7 (Phospholipase A2, group VII) gene located at 6q21 region that encodes for Lp-PLA(2), an inflammatory protein; inflammatory genes, namely IL20RA, IL22RA2, IFNGR1, TNFAIP3 in the 6q23 chromosomal region, the CRP gene located at 8q24 and the *MEF2A* (myocyte enhancer factor 2A) and *HSP90B2P* (heat shock protein90B2P) genes on the 15q26 chromosomal region are considered to be some of the important atherothrombotic genes.

Table 2. List of potential Chromosomal loci showing suggestive evidence of linkage to CAD (p value ≤ 0.05).

Marker	Map position (cM)	LOD score	P value	Chromosomal loci
D1S2836	285.75	0.57	0.05	1p36.3
D4S392*	78.97	0.98	0.02	4q21.21
D5S419	39.99	0.60	0.05	5p13.1
D6S462	99.01	0.83	0.03	6q16.1-q16.3
D6S292*	136.97	1.21	0.009	6q22.33
D6S262*	130.0	1.02	0.02	6q23
D6S308	144.46	1.13	0.011	6q24.2
D6S1574	9.18	0.67	0.04	6p25.1
D6S309	14.07	0.60	0.05	6p25.3
D8S1784	118.15	0.78	0.03	8q23
D8S270	103.69	0.64	0.04	8q21.3
D8S514*	130.0	0.98	0.02	8q24.1
D12S1723	164.63	0.64	0.04	12q24.3
D13S1265	98.82	0.73	0.03	13q32.2
D15S120	112.58	0.80	0.03	15q26
D15S205	78.92	0.56	0.05	15q24
D21S263	27.40	0.71	0.04	21q21.3
DXS991	52.50	0.80	0.03	Xp11.22
DXS1060	15.12	0.64	0.04	Xp22.3
DXS987	22.18	0.59	0.05	Xp22.2
DXS1126	27.59	0.56	0.05	Xp22

*potential loci with LOD score ~ 1

Table 3. List of QTL loci showing suggestive evidence of linkage to various atherothrombotic biomarkers (p value \leq 0.05).

Biomarker	Marker	Chromosomal Loci	LOD Score
Total Cholesterol	DXS1060	Xp22.3	1.07
	DXS8051	Xp22.3-p22.2	1.69
	DXS1214	Xp21.2	0.88
	DXS990	Xp11.22 / Xq13.1-q21	0.88
	D5S433	5q11.2-q13.3	1.04
	D7S484	7p15-p14	1.03
	D7S510	7p14-p13	1.05
	D19S420	19q13.1-q13.2	0.91
Triglycerides	DXS986	Xq13.1-q21	1.1
	DXS990	Xp11.22 / Xq13.1-q21	0.88
	D4S426	4q35	0.9
Low-Density Lipoprotein-cholesterol	D7S513	7p21.3	1.11
	D7S493	7p21	1.08
	D7S560	7p11	1
	D9S161	9p21.2	0.98
	DXS986	Xq13.1-q21	1.06
	DXS990	Xp11.22 / Xq13.1-q21	1.02
High Density Lipoprotein-cholesterol	D2S112	2q21-q22	0.93
	D11S904	11p14.2	1.26
	D19S418	19q13.4	0.94
Apolipoprotein A1	D3S1267	3q13.2-q21	1.06
	D4S391	4p14	0.95
	D4S392	4q	1.19
	D4S2964	4q21.1	1.05
	D6S470	6p24.3	1.02
	D13S156	13q22, 13q	0.93
	D15S130	15q25-q26, 15q23-q26.3 / 7p15.3	0.93
	D19S221	19p13.2	1.018
Apolipoprotein B100	DXS986	Xq13.1-q21	1.21
	DXS990	Xp11.22 / Xq13.1-q21	1.05
	D13S175	13p12	0.92
Factor VII.c	D5S406	5q11.2-q13.3	0.9
	D6S434	6q16.3-q21	0.98
	D13S159	13q32.2	0.89
Fibrinogen	D1S2785	1q41-q42	1.03
	D1S2842	1q42.2-q43 / 11p15.1	1.48
	D4S405	4p14 / 4p15.1 - q12	1.02
	D12S86	12q24	1.08
	D15S131	15q23	0.9
Secretory Phospholipase A II	D12S83	12p13.2-q24.1	0.88
	D15S1007	15q12-q15	0.94

Interleukin 6	D2S112	2q21-q22	0.9
	D2S2330	2q23-q24	1.3
	D6S1581	6q24	0.9
	D9S1826	9q, 9q34, 9q34.3	1.01
Lipoprotein(a)	D7S513	7p21.3	1.11
	D7S493	7p15, 7p21	1.08
	D7S516	7p15.2-p15.1	1
	D9S161	9p21.2 / 17q22-24	0.98
	DXS986	Xq13.1-q21	1.06
	DXS990	Xp11.22 / Xq13.1-q21	1.02
High sensitive C-reactive protein	D2S165	2p21-p22	0.95
	D8S284	8q24	0.88
Diastolic blood pressure	D2S391	2p16-p21	0.89
	DXS1001	Xq24-q25, Xq27	0.88
Systolic blood pressure	D4S1592	4q12	0.99
	D8S505	8q13	1.16
	D13S153	13q14.2	1.03
	D14S985	14q32-q32.2	0.93
	D14S292	14q22-21	0.92
	D15S1012	15q13.1-q15.1	1
Body Mass Index	D18S53	18p11.32-p11.23	1.16
	D1S468	1p36.3	0.98
Waist Hip Ratio	D6S470	6p24.3	0.89
	D12S86	12q15-14	0.88




Figure 3. QTL analysis showing suggestive evidence of linkage of various chromosomal loci for the atherothrombotic biomarkers. Arrow denotes evidence of linkage of plasma FVII.c levels to 13q32.2 region.

Discussion

We carried out pilot linkage study using affected sibling pairs showing premature onset of CAD, selected from six Asian Indian families with a positive family history for CVD. To our knowledge, this is the first study of its kind, performed on the Indian population. We have identified several potential loci with suggestive evidence of linkage to CAD in the present study. Despite the low power of the study due to the small sample size and no single locus passing the threshold for

confirmed linkage to CAD, we were able to identify several putative loci that have been reported to harbor putative candidate genes regulating inflammation and immune response process. This finding is of particular importance given our current understanding of atherosclerosis as a chronic inflammatory and auto-immune disease (41, 42).

There are several positive aspects to the study. Presence of family history has been traditionally considered as an independent risk factor for CAD (1). In the IARS, all subjects have

a strong family history of CVD, which can possibly enrich the CAD associated genes. Another important aspect is the selection of CAD affected subjects with premature onset of the disease; the average age at onset for CAD in the present study was around 50 years for males and less than 60 years for females.

Given the difficulty in recruiting large multi generation families, affected sibling pairs offer an attractive alternative method to conventional multi-generation pedigrees for undertaking linkage studies. The underlying basis of this method is the analysis of the pattern of sharing of risk alleles between the affected sibling pairs. Such an approach has been popular across various studies on CAD (4, 6-10, 43). An important consideration here is that since CAD is a late-onset disease, the parental generation may not be alive for participation in the study. In such an instance, siblings rather than parents-offspring-trios may be useful for linkage analysis. Furthermore, such studies also facilitate investigation on contributions of environmental factors, given that proband and their siblings belong to the same generation, may be of comparable age and might be exposed to similar environmental triggers. Furthermore, multi-point linkage analysis that simultaneously uses multiple markers to test for linkage at any given chromosomal locus serves as a powerful tool as it utilizes the haplotype information to infer IBD relation between affected sibling pairs (44).

Using the powerful tool of bioinformatics and the enormous genetic data available in public domain such as NCBI, we identified several interesting genes surrounding loci that showed suggestive evidence of linkage to CAD in the present study. For example, the PLA2G7 gene located on 6q21.1 chromosomal region encodes for the inflammatory protein, Lp-PLA(2). Over 25 prospective epidemiological studies have demonstrated the association of elevated Lp-PLA(2) levels with primary CVD events, recurrent events and stroke as reviewed by Corsan et al (45). The PLA2G7 was shown to be a potential functional candidate gene for CAD based on independent replication in two large cohorts, the CATHGEN and GENECARD (46). Further, strong multivariate-association was shown with Lp-PLA(2) activity for MEF2A (myocyte-specific enhancer factor-2), a DNA binding regulatory protein directed towards muscle-specific genes, in the Framingham Heart Study (47). Interestingly, the MEF2A gene is located within the 15q26 region that is yet another potential locus identified in the present study. In addition, inflammatory genes such as the IL20RA, IL22RA2, IFNGR1 and TNFAIP3 that play a key role in inflammation-induced atherosclerosis are also known to reside in the 6q23 region. Other salient findings include the 4q21 locus that harbors the APOA1 gene and the 8q24 locus that harbors the CRP gene, both of which are considered as important biomarkers of CAD progression (48-51).

We obtained suggestive evidence of linkage at the 13q32.1 locus for the FVII.c phenotype by QTL analysis. It is of interest to note that QTL analysis carried out previously in a subset of the IARS cohort showed suggestive linkage evidence of F7 SNP with FVII.c levels (LOD score = 1.82; $P = 0.002$) (17).

In conclusion, although the results of our pilot linkage study on genome wide scan using microsatellite markers in a selective cohort of Asian Indians is initial; they have helped to identify interesting loci showing suggestive evidence of linkage to CAD. These loci are known to harbor critical genes associated with inflammation and immune response which is in tune with our current understanding that atherosclerosis is an infection-mediated immuno-modulatory disease (52-55). Our early findings provide a basis for further investigations on a larger ASPs cohort already enrolled in the IARS. These findings will be integrated with the ongoing study on candidate genes, supported by functional and gene expression studies. Additionally, in depth bioinformatics analysis will be carried out on published linkage, QTL and genome wide association datasets to correlate and gauge the true potential of the interesting loci obtained in the present study. Such a convergent genomic approach will help to define a prioritized list of genetic markers for better risk stratification in the Asian Indian population.

Acknowledgements

We gratefully acknowledge the constant encouragement given by the trustees of Thrombosis Research Institute, London and Bangalore and the financial support received from Gary Weston foundation and the Tata Social Welfare Trust. We are grateful for the training provided at the Third Fogarty Indo-US Workshop on 'Genetic Epidemiological methods for dissection of Complex Human Traits' organized by Prof. Partha Majumder, Professor and Head, Human Genetics Unit, Indian Statistical Institute, Kolkata, India, that enabled us to carry undertake linkage analysis. We thank all investigators, staff, administrative teams and participants of the IARS from Narayana Hrudayalaya, Bangalore and Asian Heart Centre, Mumbai for their valuable contributions. We are grateful to the patients, their family members and the unaffected subjects for participating in the study.

Funding

We are grateful for the Institutional grant received from the Tata Social Welfare Trust, India (TSWT/IG/SNB/JP/Sdm). The program grant received from the Department of Biotechnology, Ministry of Science and Technology, Government of India (BT/PR5864/Med/14/706/2005) was par-

ticularly helpful in carrying out the present study. The sponsors did not participate in the design, conduct, sample collection analysis and interpretation of the data or in the preparation, review or approval of the manuscript.

Competing Interests

The authors have no conflicts of interest to disclose.

References

1. Shea, S., Ottman, R., Gabrieli, C., Stein, Z., and Nichols, A. (1984) Family history as an independent risk factor for coronary artery disease. *J Am Coll Cardiol* 4, 793-801
2. Shanker, J., Kanjilal, S., Rao, V. S., Perumal, G., Khadrinarasimhiah, N. B., et al. (2007) Adult nontwin sib concordance rates for type 2 diabetes, hypertension and metabolic syndrome among Asian Indians: the Indian Atherosclerosis Research Study. *Vasc Health Risk Manag* 3, 1063-1068
3. Blackwelder, W. C., and Elston, R. C. (1985) A comparison of sib-pair linkage tests for disease susceptibility loci. *Genet Epidemiol* 2, 85-97
4. Pajukanta, P., Cargill, M., Viitanen, L., Nuotio, I., Kareinen, et al. (2000) Two loci on chromosomes 2 and X for premature coronary heart disease identified in early- and late-settlement populations of Finland. *Am J Hum Genet* 67, 1481-1493
5. Francke, S., Manraj, M., Lacquemant, C., Lecoecur, C., Lepretre, F., et al. (2001) A genome-wide scan for coronary heart disease suggests in Indo-Mauritians a susceptibility locus on chromosome 16p13 and replicates linkage with the metabolic syndrome on 3q27. *Hum Mol Genet* 10, 2751-2765
6. Harrap, S. B., Zammit, K. S., Wong, Z. Y., Williams, F. M., Bahlo, M., et al. (2002) Genome-wide linkage analysis of the acute coronary syndrome suggests a locus on chromosome 2. *Arterioscler Thromb Vasc Biol* 22, 874-878
7. Broeckel, U., Hengstenberg, C., Mayer, B., Holmer, S., Martin, L. J., et al. (2002) A comprehensive linkage analysis for myocardial infarction and its related risk factors. *Nat Genet* 30, 210-214
8. Wang, L., Hauser, E. R., Shah, S. H., Pericak-Vance, M. A., Haynes, C., et al. (2007) Peakwide mapping on chromosome 3q13 identifies the kalirin gene as a novel candidate gene for coronary artery disease. *Am J Hum Genet* 80, 650-663
9. Hauser, E. R., Crossman, D. C., Granger, C. B., Haines, J. L., Jones, C. J., et al. (2004) A genomewide scan for early-onset coronary artery disease in 438 families: the GENECARD Study. *Am J Hum Genet* 75, 436-447
10. Shah, S. H., Freedman, N. J., Zhang, L., Crosslin, D. R., Stone, D. H., et al. (2009) Neuropeptide Y gene polymorphisms confer risk of early-onset atherosclerosis. *PLoS Genet* 5, e1000318
11. Connelly, J. J., Shah, S. H., Doss, J. F., Gadson, S., Nelson, S., et al. (2008) Genetic and functional association of FAM5C with myocardial infarction. *BMC Med Genet* 9, 33
12. Wang, L., Fan, C., Topol, S. E., Topol, E. J., and Wang, Q. (2003) Mutation of MEF2A in an inherited disorder with features of coronary artery disease. *Science* 302, 1578-1581
13. Shah, S. H., Kraus, W. E., Crossman, D. C., Granger, C. B., Haines, J. L., et al. (2006) Serum lipids in the GENECARD study of coronary artery disease identify quantitative trait loci and phenotypic subsets on chromosomes 3q and 5q. *Ann Hum Genet* 70, 738-748
14. Yang, R., Li, L., Seidelmann, S. B., Shen, G. Q., Sharma, S., et al. A genome-wide linkage scan identifies multiple quantitative trait loci for HDL-cholesterol levels in families with premature CAD and MI. *J Lipid Res* 51, 1442-1451
15. Lin, J. P. (2003) Genome-wide scan on plasma triglyceride and high density lipoprotein cholesterol levels, accounting for the effects of correlated quantitative phenotypes. *BMC Genet* 4 Suppl 1, S47
16. Maitra, A., Shanker, J., Dash, D., John, S., Sannappa, P. R., et al. (2008) Polymorphisms in the IL6 gene in Asian Indian families with premature coronary artery disease - The Indian Atherosclerosis Research Study. *Thromb Haemost* 99, 944-950
17. Shanker, J., Perumal, G., Maitra, A., Rao, V. S., Natesha, B. K., et al. (2009) Genotype-phenotype relationship of F7 R353Q polymorphism and plasma factor VII coagulant activity in Asian Indian families predisposed to coronary artery disease. *J Genet* 88, 291-297
18. McQueen, M. B., Bertram, L., Rimm, E. B., Blacker, D., and Santangelo, S. L. (2003) A QTL genome scan of the metabolic syndrome and its component traits. *BMC Genet* 4 Suppl 1, S96
19. Bielinski, S. J., Lynch, A. I., Miller, M. B., Weder, A., Cooper, R., et al. (2005) Genome-wide linkage analysis for loci affecting pulse pressure: the Family Blood Pressure Program. *Hypertension* 46, 1286-1293
20. Chandak, G. R., Ward, K. J., Yajnik, C. S., Pandit, A. N., Bavdekar, A., et al. (2006) Triglyceride associated polymorphisms of the APOA5 gene have very different allele frequencies in Pune, India compared to Europeans. *BMC Med Genet* 7, 76
21. Maitra, A., Dash, D., John, S., Sannappa, P. R., Das, A. P., et al. (2009) A Common Variant in Chromosome 9p21 Associated with Coronary Artery Disease in Asian Indians. *In J Genet*
22. Maitra, A., Shanker, J., Dash, D., John, S., Sannappa, P. R., et al. (2008) Polymorphisms in the IL6 gene in Asian Indian families with premature coronary artery disease--the Indian Atherosclerosis Research Study. *Thromb Haemost* 99, 944-950
23. Radha, V., Vimalaswaran, K. S., Babu, H. N., Abate, N., Chandalia, M., et al. (2006) Role of genetic polymorphism peroxisome proliferator-activated receptor-gamma2 Pro12Ala on ethnic susceptibility to diabetes in South-Asian and Caucasian subjects: Evidence for heterogeneity. *Diabetes Care* 29, 1046-1051
24. Shanker, J., Perumal, G., Rao, V. S., Khadrinarasimhiah, N. B., John, S., et al. (2008) Genetic studies on the APOA1-C3-A5 gene cluster in Asian Indians with premature coronary artery disease. *Lipids Health Dis* 7, 33
25. Agrawal, S., Singh, V. P., Tewari, S., Sinha, N., Ramesh, V., et al. (2004) Angiotensin-converting enzyme gene polymorphism in coronary artery disease in north India. *Indian Heart J* 56, 44-46
26. Banerjee, I., Pandey, U., Hasan, O. M., Parihar, R., Tripathi, V., et al. (2007) Association between inflammatory gene polymorphisms and coronary artery disease in an Indian population. *J Thromb Thrombolysis*
27. Consortium, I. G. V. (2008) Genetic landscape of the people of India: a canvas for disease gene exploration. *Journal of Genetics* 87, 3-18
28. Kumar, P., Luthra, K., Dwivedi, M., Behl, V. K., Pandey, et al. (2003) Apolipoprotein E gene polymorphisms in patients with premature myocardial infarction: a case-controlled study in Asian Indians in North India. *Ann Clin Biochem* 40, 382-387
29. Mukherjee, M., and Shetty, K. R. (2004) Variations in high-density lipoprotein cholesterol in relation to physical activity and Taq 1B polymorphism of the cholesteryl ester transfer protein gene. *Clin Genet* 65, 412-418
30. Padmaja, N., Kumar, R. M., Balachander, J., and Adithan, C. (2009) Cholesteryl ester transfer protein Taq1B, -629C>A and I405V polymorphisms and risk of coronary heart disease in an Indian population. *Clin Chim Acta*
31. Periaswamy, R., Gurusamy, U., Shewade, D. G., Cherian, A., Swaminathan, R. P., et al. (2008) Gender specific association of endothelial nitric oxide synthase gene (Glu298Asp) polymorphism with essential hypertension in a south Indian population. *Clin Chim Acta* 395, 134-136
32. Sanghera, D. K., Saha, N., Aston, C. E., and Kamboh, M. I. (1997) Genetic polymorphism of paraoxonase and the risk of coronary heart disease. *Arterioscler Thromb Vasc Biol* 17, 1067-1073
33. Sankar, V. H., Girisha, K. M., Gilmour, A., Singh, V. P., Sinha, N., et al. (2005) TNFR2 gene polymorphism in coronary artery disease. *Indian J Med Sci* 59, 104-108

34. Kumar, N. K. (2006) Bioethics activities in India. *East Mediterr Health J* 12 Suppl 1, S56-65
35. Miller, S. A., Dykes, D. D., and Polesky, H. F. (1988) A simple salting out procedure for extracting DNA from human nucleated cells. *Nucleic Acids Res* 16, 1215
36. O'Connell, J. R., and Weeks, D. E. (1998) PedCheck: a program for identification of genotype incompatibilities in linkage analysis. *Am J Hum Genet* 63, 259-266
37. Abecasis, G. R., Cherny, S. S., Cookson, W. O., and Cardon, L. R. (2002) Merlin--rapid analysis of dense genetic maps using sparse gene flow trees. *Nat Genet* 30, 97-101
38. Mukhopadhyay, N., Almasy, L., Schroeder, M., Mulvihill, W. P., and Weeks, D. E. (2005) Mega2: data-handling for facilitating genetic linkage and association analyses. *Bioinformatics* 21, 2556-2557
39. Kruglyak, L., Daly, M. J., Reeve-Daly, M. P., and Lander, E. S. (1996) Parametric and nonparametric linkage analysis: a unified multipoint approach. *Am J Hum Genet* 58, 1347-1363
40. Friedewald, W. T., Levy, R. I., and Fredrickson, D. S. (1972) Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. *Clin Chem* 18, 499-502
41. Hansson, G. K. (2005) Inflammation, atherosclerosis, and coronary artery disease. *N Engl J Med* 352, 1685-1695
42. Ross, R. (1999) Atherosclerosis--an inflammatory disease. *N Engl J Med* 340, 115-126
43. Farrall, M., Green, F. R., Peden, J. F., Olsson, P. G., Clarke, R., et al. (2006) Genome-wide mapping of susceptibility to coronary artery disease identifies a novel replicated locus on chromosome 17. *PLoS Genet* 2, e72
44. Halpern, J., and Whittemore, A. S. (1999) Multipoint linkage analysis. A cautionary note. *Hum Hered* 49, 194-196
45. Corson, M. A., Jones, P. H., and Davidson, M. H. (2008) Review of the evidence for the clinical utility of lipoprotein-associated phospholipase A2 as a cardiovascular risk marker. *Am J Cardiol* 101, 41F-50F
46. Sutton, B. S., Crosslin, D. R., Shah, S. H., Nelson, S. C., Bassil, A., et al. (2008) Comprehensive genetic analysis of the platelet activating factor acetylhydrolase (PLA2G7) gene and cardiovascular disease in case-control and family datasets. *Hum Mol Genet* 17, 1318-1328
47. Schnabel, R., Dupuis, J., Larson, M. G., Lunetta, K. L., Robins, S. J., et al. (2009) Clinical and genetic factors associated with lipoprotein-associated phospholipase A2 in the Framingham Heart Study. *Atherosclerosis* 204, 601-607
48. Goswami, B. Apolipoproteins: emerging biomarkers for CAD. *Singapore Med J* 51, 179
49. Patel, J. V., Abraheem, A., Creamer, J., Gunning, M., Hughes, E. A., et al. Apolipoproteins in the discrimination of atherosclerotic burden and cardiac function in patients with stable coronary artery disease. *Eur J Heart Fail* 12, 254-259
50. Ridker, P. M. (2007) C-reactive protein and the prediction of cardiovascular events among those at intermediate risk: moving an inflammatory hypothesis toward consensus. *J Am Coll Cardiol* 49, 2129-2138
51. Ridker, P. M., and Silvertown, J. D. (2008) Inflammation, C-reactive protein, and atherothrombosis. *J Periodontol* 79, 1544-1551
52. Chyu, K. Y., Nilsson, J., and Shah, P. K. Immune mechanisms in atherosclerosis and potential for an atherosclerosis vaccine. *Discov Med* 11, 403-412
53. Hansson, G. K., and Nilsson, J. (2009) Vaccination against atherosclerosis? Induction of atheroprotective immunity. *Semin Immunopathol* 31, 95-101
54. Keaney, J. F., Jr. Immune modulation of atherosclerosis. *Circulation* 124, e559-560
55. Shah, P. K., Chyu, K. Y., Fredrikson, G. N., and Nilsson, J. (2005) Immunomodulation of atherosclerosis with a vaccine. *Nat Clin Pract Cardiovasc Med* 2, 639-646

Follow us:



At Medicalia.org

Doctors exchange clinical experiences, review their cases and share clinical knowledge. You can also access lots of medical publications for free. Join Now! <http://medicalia.ning.com/>

Publish with iMedPub

<http://www.imedpub.com>

- ✓ Translational Biomedicine (TBM) is an international, peer-reviewed, Open access journal with world famous scientist on the editorial board.
- ✓ TBM publishes high quality articles from all areas and fields which have an impact to understand human biology, pathogenesis, diagnosis and treatment for human diseases.
- ✓ Event's proceedings and abstracts are also published.
- ✓ TBM welcomes researchers and experts from clinical side to submit their manuscripts for rapid publication.

Submit your manuscript here:

<http://www.transbiomedicine.com>